Don’t Give This to Your Daughter – Despite What Your Doctor Says

Joseph Mercola

9/17/2011

It’s been four years since Gardasil debuted as a blockbuster vaccine with sales that rocketed to over $1.1 billion in its first nine months.

Touted as a wonder vaccine that would end cervical cancer, it was supposed to be the savior of both mankind and Merck’s Vioxx-damaged bottom line. But now, according to CNN Money, it’s a dud.

It just posted $219 million in sales. But in the pharma world, that’s a paltry pittance, nothing short of an in-flight explosion that’s caused Merck stock to drop 3 percent, with analysts and investors scrambling to figure out what went wrong.

So what happened?

How did a vaccine that was supposed to be Merck’s beacon for higher profits in the 21^st Century go from flagship to flop?

And now… the rest of the story. …..

Advertisement